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Abstract
Background: TNFα may contribute to the pathophysiology of airway inflammation. For example,
we have recently shown that nasal administration of TNFα produces late phase co-appearance of
granulocyte and plasma exudation markers on the mucosal surface. The objective of the present
study was to examine indices of granulocyte presence and activity in response to intranasal TNFα
challenge.
Methods: Healthy subjects and patients with allergic rhinitis (examined out of season) were
subjected to nasal challenge with TNFα (10 μg) in a sham-controlled and crossover design. Nasal
lavages were carried out prior to and 24 hours post challenge. Nasal biopsies were obtained post
challenge. Nasal lavage fluid levels of myeloperoxidase (MPO) and eosinophil cationic protein (ECP)
were analyzed as indices of neutrophil and eosinophil activity. Moreover, IL-8 and α2-macroglobulin
were analyzed as markers of pro-inflammatory cytokine production and plasma exudation. Nasal
biopsy numbers of neutrophils and eosinophils were monitored.
Results: Nasal lavage fluid levels of MPO recorded 24 hours post TNFα challenge were increased
in healthy subjects (p = 0.0081) and in patients with allergic rhinitis (p = 0.0081) (c.f. sham
challenge). Similarly, α2-macroglobulin was increased in healthy subjects (p = 0.014) and in patients
with allergic rhinitis (p = 0.0034). Lavage fluid levels of ECP and IL-8 were not affected by TNFα
challenge. TNFα increased the numbers of subepithelial neutrophils (p = 0.0021), but not the
numbers of eosinophils.
Conclusion: TNFα produces a nasal inflammatory response in humans that is characterised by late
phase (i.e., 24 hours post challenge) neutrophil activity and plasma exudation.
Background
Tumour necrosis factor-α (TNFα) is an important pro-
inflammatory cytokine of the immune system. Dysregu-
lated TNFα responses are implicated in several inflamma-
tory diseases including rheumatoid arthritis. In this
condition, TNFα antagonism, either with recombinant
Published: 30 January 2008
Respiratory Research 2008, 9:15 doi:10.1186/1465-9921-9-15
Received: 6 November 2007
Accepted: 30 January 2008
This article is available from: http://respiratory-research.com/content/9/1/15
© 2008 Widegren et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2008, 9:15 http://respiratory-research.com/content/9/1/15
Page 2 of 8
(page number not for citation purposes)
soluble receptors or neutralising antibodies, improves dis-
ease activity scores [1].
In human bronchial airways, TNFα is produced by several
cell types including macrophages [2], eosinophils [3,4],
epithelial cells [5,6], and mast cells [7,8]. Inhalation of
TNFα produces a response that is characterized by
increased sputum numbers of granulocytes and increased
airway responsiveness [9,10]. Furthermore, in refractory
asthma, treatment with etanercept, an anti-TNFα meas-
ure, is associated with improvement in asthma symptoms,
lung function, and airway hyperresponsiveness [11,12].
While these observations suggest an association between
TNFα and bronchial airway inflammation, little is known
about TNFα-induced nasal airway responses in man.
Focusing on human nasal airways, patients suffering from
allergic rhinitis have been shown to feature increased tis-
sue expression of TNFα mRNA and increased nasal
mucosal output of TNFα [13-15]. Furthermore, in a pre-
liminary study, we have shown that while nasal challenge
with TNFα fails to produce acute effects, it produces late-
phase plasma exudation (i.e., extravasation and luminal
entry of plasma) [16], a response characteristic of on-
going inflammation [17]. We have also observed that this
response may be associated with increased nasal mucosal
output of granulocyte mediators [16]. While our observa-
tions suggest a role for TNFα in upper airway conditions
characterised by inflammation, information on the nature
of this response is scarce. Further information in this field
is warranted for several reasons: it may be used to deter-
mine whether or not anti-TNF measures should be evalu-
ated for upper respiratory tract conditions. Furthermore,
studies in allergic rhinitis may elucidate specific roles for
TNFα in type-1 allergic inflammation, which may not be
done in allergic asthma where type-1 features may be
blurred by chronic inflammatory features.
The aim of the present study was to examine characteris-
tics of the inflammatory process evoked by human nasal
administration of TNFα. Nasal challenges with TNFα were
carried out and the response was monitored by nasal lav-
ages and biopsies and by analysis of granulocyte activa-
tion and plasma exudation markers as well as tissue
numbers of granulocytes. Based on our previous study
[16], we focused the evaluation on an observation point
24 hours post challenge. Healthy subjects and patients
with allergic rhinitis (examined out of season) were
included in order to get a preliminary estimation regard-
ing whether or not these group of subjects differ with
regard to TNFα-induced effects.
Methods
Study Design
The present study involved nasal administration of a sin-
gle dose of TNFα (10 μg) in a single blind, sham-control-
led (isotonic saline), randomized, and crossover design
with a two-week washout period. Nasal lavages were car-
ried out prior to and 24 hours post challenge. Further-
more, nasal mucosal biopsies were obtained 24 hours
post-challenge. Lavage fluid levels of myeloperoxidase
(MPO), eosinophil cationic protein (ECP), α2-macroglob-
ulin, and IL-8 were measured as indices of neutrophil
activity, eosinophil activity, plasma exudation, and pro-
inflammatory cytokine production, respectively. Num-
bers of neutrophils and eosinophils in the biopsy material
were determined. Nasal symptoms were scored at strategic
time-points (below).
Subjects
Thirteen healthy subjects (5 females, 8 males, aged 20–28
years) and 14 patients with seasonal allergic rhinitis (8
females, 6 males, aged 23–45 years) participated in the
study. The protocol was approved by the Regional Ethics
Committee and written informed consent was obtained.
The study was carried out in compliance with the Helsinki
Declaration. For healthy subjects, inclusion criteria were:
negative skin prick-test, normal nasal examination, and
use of contraceptives (for females). Exclusion criteria
were: history of respiratory tract infection within seven
days of the start of the study, allergic and non-allergic
rhinitis, other nasal disease (structural abnormalities, rhi-
nosinusitis, and polyposis), use of decongestants within
seven days of the start of the study, and use of other treat-
ments (except occasional analgesics) within one month of
the start of the study. For patients with allergic rhinitis,
inclusion and exclusion criteria were the same as
described above except that these subjects presented a his-
tory of at least two years of seasonal allergic rhinitis and a
positive skin-prick test to relevant allergens (patients with
positive tests for perennial allergens were excluded).
Accordingly, eleven of the allergic subjects were skin-prick
positive for both birch and timothy grass allergen,
whereas one was sensitized to birch alone and one to tim-
othy grass alone. None of the individuals had positive
tests for house dust mite. Eight subjects had positive skin-
prick tests for either cat or dog dander, but none of them
were exposed to these animals on a regular basis.
TNFα challenge
Recombinant human TNFα (210-TA/CF, R&D Systems,
Abingdon, UK) was diluted with isotonic saline to a 100
μg/ml concentration. The solution was prepared less than
one hour before the challenge and it was administered
using a spray-device delivering 100 μl per actuation. The
dose of 10 μg of TNFα was based on experience from our
previous study [16]. Isotonic saline was used for the shamRespiratory Research 2008, 9:15 http://respiratory-research.com/content/9/1/15
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challenge. The challenges were given in a randomized
order. The right hand side nasal cavity was challenged at
the first visit and the left hand side at the second visit. The
reason for using both nasal cavities was to avoid any influ-
ence of the first biopsy on the second challenge and sam-
pling procedure. A washout period of two weeks was
instituted between the challenges to make the repeated
biopsy procedure more tolerable.
Symptom scores
Nasal symptoms were scored by the subjects prior to
TNFα challenge and 24 hours thereafter. Sneezes, secre-
tion, and blockage were each scored on a four-graded
scale: 0 for no symptoms, 1 for mild symptoms, 2 for
moderate symptoms, and 3 for severe symptoms. The
scores were added to a total nasal symptom score (range
0–9).
Nasal lavages
Nasal lavages with isotonic saline were carried out using a
pool-device [18]. The volume of the pool-fluid was 15 ml
and it was kept in the nasal cavity for 5 min at each occa-
sion. The lavages were performed immediately after the
symptom scoring, before the challenge and before the
nasal biopsy at 24 hours. The recovered fluid was centri-
fuged and the supernatant was homogenized, prepared in
aliquots, and frozen (-30°C) for later analysis. The results
were expressed as weight of analyte per volume without
correction for any dilution of the lavage fluid: correction
for dilution may be of little importance when high vol-
ume lavages are employed.
Nasal biopsies
The biopsy was obtained immediately after the second
nasal lavage. Topical anaesthesia was applied using a solu-
tion of lidocaine hydrochloride (34.0 mg/ml) and nafazo-
line (0.17 mg/ml), delivered first by a spray-device and
thereafter by a cotton swab. The biopsies were taken from
the inferior aspect of the inferior turbinate about 0.5 cm
from its anterior margin using a cutting-punch forceps
with a drilled out punch (2 mm in diameter). Haemosta-
sis was achieved using diathermy.
Analysis
α2-Macroglobulin was measured using a RIA sensitive to
7.8 ng/ml. Rabbit anti-human α2-macroglobulin (Dako,
Copenhagen, Denmark) was used as anti-serum and
human serum (Behringwerke, Marburg, Germany) as
standard. Human α2-macroglobulin (Capell-Organon,
Turnhout, Belgium) was iodinated. Tracer and standard or
sample was mixed with antiserum before adding goat
anti-rabbit anti-serum (AstraZeneca, Lund, Sweden). The
bound fraction was measured using a gamma counter.
The intra- and inter-assay coefficients of variation are
between 3.8–6.0% and 3.1–7.2%, respectively. IL-8 was
measured using a commercially available enzyme-linked
immunosorbent assay (R&D Systems, Abingdon, UK).
ECP and MPO were also measured using commercially
available assays (Phadia, Uppsala, Sweden and Calbio-
chem, Darmstadt, Germany, repectively). The limits of
detection for IL-8, ECP and MPO were 31.2 pg/ml, 2.0
and 1.6 ng/ml, respectively.
The biopsies were immersed overnight in buffered 4%
paraformaldehyde (pH 7.2), dehydrated in increasing
concentrations of ethanol, embedded in paraffin, and
sliced in 3 μm sections. After rinsing in TRIS-buffered
saline, the sections were incubated with primary mono-
clonal antibodies overnight at 4°C. The monoclonal anti-
body EG2 (Phadia, dilution 1:200), which detects the
eosinophil granule protein ECP, was used to identify eosi-
nophils. Neutrophils were detected by a monoclonal anti-
body against the neutrophil granule protein MPO (Dako,
A390, dilution 1:8000). After incubation with primary
antibodies specimens were rinsed in TBS buffer and incu-
bated with a secondary antibody (rabbit anti-mouse,
Dako Z0109, dilution 1:80) for 40 min at room tempera-
ture. After washing in TBS the sections were incubated in
mouse APAAP (Dako D0651, dilution 1:50 in 20% NHS)
for 30 min, rinsed, and developed using New Fuchsin
(Dako) as substrate. Endogenous alkaline phosphatase
activity was inhibited by Levamisol (Dako). All sections
were counter-stained with Harris's haematoxylin, coated
with Aqua Perm mountant (484975 Life Sci. Interna-
tional), dried overnight, and mounted in Kaiser's glycerol
gelatin (Merck, Darmstadt, Germany). The sections were
blinded and the numbers of ECP-positive (eosinophils)
and MPO-positive (neutrophils) subepithelial cells were
counted down to a depth of 210 μm below the epithelial
basement membrane. The numbers of eosinophils and
neutrophils were expressed as cells/mm2 of tissue com-
partment.
Statistics
Differences in nasal lavage fluid levels of MPO, ECP, IL-8,
and α2-macroglobulin as well as biopsy numbers of neu-
trophils and eosinophils, between observations following
TNFα and sham challenge, were analyzed using the Wil-
coxon signed rank test. A p-value less than 0.05 was con-
sidered significant. Data is presented as mean ± S.E.M.
Results
One patient with allergic rhinitis was excluded from the
study because of airway infection. Otherwise, all individ-
uals complied with the protocol. Nasal administration of
TNFα did not produce any nasal symptoms: score 0.8 ±
0.3 post sham challenge and score 0.8 ± 0.2 post TNFα
(range 0–9).Respiratory Research 2008, 9:15 http://respiratory-research.com/content/9/1/15
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Nasal lavage fluid levels of MPO recorded 24 hrs post
TNFα challenge were increased in healthy subjects (p =
0.0081) and in patients with allergic rhinitis (p = 0.0081)
(c.f. sham challenge) (Fig. 1). Furthermore, α2-mac-
roglobulin was increased in both these study groups (p =
0.014 and p = 0.0034, respectively) (Fig. 2), indicating
plasma exudation. ECP and IL-8 were not affected by
TNFα challenge (Figs. 3 and 4).
TNFα increased the numbers of subepithelial neutrophils
in the study material as a whole (p = 0.0021) (Fig. 5): a
subgroup analysis revealed that this change reflected a sta-
tistically significant increase in the healthy group (p =
0.0015), but not in the allergic rhinitis group (p = 0.204)
(Fig. 6). Nasal biopsy numbers of eosinophils were unaf-
fected by the TNFα challenge (Fig. 7). (Note, a non-signif-
icant difference 24 hours post sham challenge between
healthy subjects and patients with allergic rhinitis also for
eosinophils (p = 0.06, Mann Whitney).) Fig. 8 shows
micrographs of nasal mucosal neutrophils and eosi-
nophils 24 hours post TNFα and sham challenge, respec-
tively.
Discussion
The present study, involving healthy subjects and patients
with allergic rhinitis, demonstrates that intranasal TNFα
produces a local inflammatory response. Our observa-
tion, together with our previous findings [16], suggests
that this effect predominantly involves recruitment and
activation of neutrophils and a low-grade exudative
response 24 hours post challenge. The observation is of
interest in terms of nasal airway defence/physiology and
in terms of whether or not TNFα should be viewed as a
pro-inflammatory factor in respiratory conditions charac-
terised by inflammation.
The dose of TNFα and the time-point for monitoring of
the present response was chosen based on our previous
observation: the 10 μg dose may be low, but has been
shown to produce inflammatory effects 24 hours post
challenge [16]. In the present study, the plasma exudation
producing effect of TNFα (10 μg) at this time-point was
confirmed. Taken together, our observations suggest that
TNFα may not per se produce acute plasma exudation in
human nasal airways (like, e.g., histamine would), but
can induce an inflammatory condition that is character-
ised by "late-phase" plasma exudation. Plasma exudation
is a specific feature of inflammation and increased levels
of plasma proteins in airway mucosal surface liquids char-
acterize allergic rhinitis and upper respiratory tract infec-
tions [19,20]. Accordingly, and supported by observations
on increased levels of TNFα in allergic rhinitis [13,14] as
well as common cold [21,22], TNFα may be a pro-inflam-
matory factor in inflammatory conditions of the nasal air-
way.
Nasal lavage fluid levels of MPO were increased 24 hours
post TNFα administration in healthy subjects and in
patients with allergic rhinitis (this study). The finding is in
agreement with our previous observation in allergic rhin-
itis, although that particular increase in MPO only
reached borderline statistical significance [16]. Moreover,
in the present study, nasal biopsy numbers of neutrophils,
in the study group as a whole, were significantly increased
post TNFα challenge further indicating a neutrophil-
active effect of this cytokine. Our finding is in agreement
with observations by Thomas et al. [9,10], who reported
sputum neutrophilia in healthy subjects as well as in
patients with mild asthma following TNFα inhalation.
Also in agreement, observations in vitro have identified
TNFα as a factor that attracts [23] and, potentially, acti-
vates [24] neutrophil granulocytes. Taken together, avail-
Nasal lavage fluid levels of MPO prior to and 24 hours post TNFα and sham challenge Figure 1
Nasal lavage fluid levels of MPO prior to and 24 hours post TNFα and sham challenge. (**p < 0.01).
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able information now indicates that TNFα can be
involved in neutrophil recruitment and activity in human
airways. We have no specific explanation for the present
numerically higher levels of MPO observed in healthy
subjects (c.f. patients with allergic rhinitis) following
TNFα challenge. However, this difference is not statisti-
cally significant (p = 0.5, Mann Whitney).
In our previous study, involving patients with allergic
rhinitis examined out of season, we observed moderately
increased lavage fluid levels of ECP 24 hours after nasal
TNFα challenge [16]. In contrast, in the present study, this
observation could not be confirmed. We have no specific
explanation for the discrepant findings, but a variable
eosinophil activity at baseline may be one option: Tho-
mas et al. observed that inhalation of TNFα to mild asth-
matics increased eosinophil infiltration [9] whereas this
was not the case in healthy subjects [10]. In the present
study, the biopsy analysis, which provides an additional
aspect of cellular activity, showed that TNFα did not pro-
duce recruitment of eosinophils. Accordingly, our overall
conclusion is that TNFα administered to patients with
allergic rhinitis out of season, when there may be some
degree of nasal eosinophilia but not at all as marked as
during season allergen exposure, does not produce any
marked pro-eosinophil effects. Further studies are war-
ranted to examine effects of TNFα on eosinophil activities,
tentatively involving patients with on-going allergic rhin-
itis.
The present study was not powered to discriminate
between healthy subjects and patients with allergic rhini-
tis, but may allow for a preliminary comparison. The only
difference in TNFα induced effects between the groups
Nasal lavage fluid levels of ECP prior to and 24 hours post TNFα and sham challenge Figure 3
Nasal lavage fluid levels of ECP prior to and 24 hours post TNFα and sham challenge.
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Nasal lavage fluid levels of α2-macroglobulin prior to and 24 hours post TNFα and sham challenge Figure 2
Nasal lavage fluid levels of α2-macroglobulin prior to and 24 hours post TNFα and sham challenge. (*p < 0.05, **p < 0.01).
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was that the nasal mucosal numbers of neutrophils were
increased in healthy subjects following TNFα challenge
but not in patients with allergic rhinitis. However, TNFα
did produce a numerical increase in neutrophils also in
allergic rhinitis, which did not reach statistical signifi-
cance (possibly due to a somewhat higher baseline). Fur-
thermore, MPO, as marker of neutrophil activity, was
significantly increased in both study groups. Taken
together, no marked differences emerged between healthy
subjects and patients with allergic rhinitis regarding
TNFα-induced effects. However, further studies may be
warranted in order to elucidate whether TNFα has a spe-
cific role in allergic airway conditions: such studies are
warranted based on observations that patients with aller-
gic rhinitis feature increased tissue expression of TNFα
mRNA and TNFα protein [13-15]. Moreover, a basis for
further exploration may be the recent observation that
mice sensitized to ovalbumin and subjected to gene ther-
apy (soluble TNFα receptor IgGFc fusion gene) present
decreased symptoms and attenuated aggregation of mast
cells, eosinophils, and IL-5 positive cells following nasal
ovalbumin challenge [25]. Tentatively, further human in
vivo  studies may involve intervention with anti-TNFα
measures in allergic rhinitis at seasonal allergen exposure.
Anti-TNFα drugs, including etanercept, have emerged as a
possible treatment option for refractory asthma [11,12]:
reduction of symptoms, improvement in lung function,
and reduction of bronchial hyperresponsiveness as a
result of anti-TNFα intervention. A similar use of anti-
TNFα drugs in allergic rhinitis is in our opinion not likely,
in part reflecting that existing treatment options are very
good and in part inherited difficulties with current anti-
TNFα approaches. However, the human nasal airway and
allergic rhinitis can be used to monitor effects of TNFα
(this study) and anti-TNFα drugs. This may be particularly
valid since there are key similarities between inflamma-
tory processes of the upper and lower airways, since obser-
vations made in upper airway conditions frequently can
Numbers of subepithelial neutrophils in nasal biopsies  obtained 24 hours post TNFα and sham challenge in healthy  subjects and patients with allergic rhinitis Figure 6
Numbers of subepithelial neutrophils in nasal biopsies 
obtained 24 hours post TNFα and sham challenge in healthy 
subjects and patients with allergic rhinitis. (**p < 0.01).
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Nasal lavage fluid levels of IL-8 prior to and 24 hours post TNFα and sham challenge.
Healthy
0
250
500
750
1000
1250
1500
1750
02 4
Sham
TNFα
Time (hrs)
Allergic Rhinitis
0
250
500
750
1000
1250
1500
1750
02 4
Sham
TNFα
Time (hrs)
Numbers of subepithelial neutrophils in nasal biopsies  obtained 24 hours post TNFα and sham challenge in the  study material as a whole Figure 5
Numbers of subepithelial neutrophils in nasal biopsies 
obtained 24 hours post TNFα and sham challenge in the 
study material as a whole. (**p < 0.01).
Healthy + Allergic Rhinitis
0
100
200
300
400
Sham TNFα
**Respiratory Research 2008, 9:15 http://respiratory-research.com/content/9/1/15
Page 7 of 8
(page number not for citation purposes)
be translated to the bronchial airway diseases, and since
nasal airway studies are easier to perform. In this context,
the present findings suggest, indirectly, that beneficial
effects of anti-TNFα drugs in refractory asthma may reflect
anti-neutrophil rather than anti-eosinophil effects.
Conclusion
Topical TNFα produces a nasal inflammatory response in
humans that potentially is mediated through increased
neutrophil activity.
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